ZNF217 and breast cancer: A detailed mechanistic analysis of the contribution of ZNF217 to therapeutic resistance combined with pre-clinical modeling will inform the design of the best treatment plan to kill these cells, thereby reducing mortality in breast cancer patients with aggressive disease.